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Comparison of health-related quality of life
among men with different co-existing
severe mental disorders in treatment for
substance use
Ana Adan1,2* , Julia E. Marquez-Arrico1 and Gail Gilchrist3
Abstract
Background: Patient-perceived health-related quality of life has become an important outcome in health care as
an indicator of treatment effectiveness and recovery for patients with substance use disorder. As no study has
assessed health-related quality of life among male patients with substance use disorder and co-existing severe
mental illness, we compared health-related quality of life among patients with substance use disorder and the
following severe mental illness diagnosis in Barcelona, Spain: schizophrenia, bipolar disorder, major depressive
disorder, and examined the associations with clinically related variables. Additionally, we compared results for health-
related quality of life in patients with substance use disorder and severe mental illness, with Spanish population norms.
Methods: We assessed 107 substance use disorder male patients using the 36-Item Short Form Health Survey
comparing results across three groups with: comorbid schizophrenia (n = 37), comorbid bipolar disorder (n = 34), and
comorbid major depressive disorder (n = 36). Multiple analyses of variance were performed to explore health-related
quality of life by the type of co-existing SMI and linear regression analyses examined clinical correlates for the 36-Item
Short Form Health Survey dimensions for each group.
Results: There were differences in Physical Functioning, Vitality and the Physical Composite Scale among groups.
Poorer Physical Functioning was observed for patients with comorbid schizophrenia (80.13±3.27) and major depressive
disorder (81.97±3.11) compared with comorbid bipolar disorder patients (94.26±1.93). Patients with substance use
disorder and schizophrenia presented lower scores in Vitality (41.6±2.80) than those with co-existing bipolar
disorder (55.68±3.66) and major depressive disorder (53.63±2.92). Finally, results in the Physical Composite Scale showed
lower scores for patients with comorbid schizophrenia (51.06±1.41) and major depressive disorder (51.99±1.87) than for
those with bipolar disorder (60.40±2.17). Moreover, all groups had poorer health-related quality of life, especially Social
Functioning, Role-Emotional and Mental Health, compared with population norms. Different clinical variables (e.g.
medical disease comorbidity, severity of addiction, psychiatric symptomatology, suicide attempts, drug relapses) were
related to different health-related quality of life dimensions depending on the co-existing severe mental illness.
(Continued on next page)
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Conclusions: Among male patients with substance use disorder, co-existing severe mental illness may influence some
health-related quality of life dimensions and clinically related variables. Such differences may require tailored
therapeutic interventions.
Keywords: Health-related quality of life, Substance use, Dual diagnosis, Schizophrenia, Bipolar disorder, Major
depressive disorder, Comorbidity
Background
Substance use disorders and severe mental illness com-
monly co-exist (65–85%) in patients seeking treatment for
either condition [1, 2]. According to previous studies, the
most common severe mental illnesses among patients
with substance use disorder were schizophrenia, bipolar
disorder and major depressive disorder [2]. These co-
existing conditions are usually referred to as dual diagno-
sis [3]. Having a dual diagnosis is strongly associated with
major clinical impairments including suicide attempts [3],
severe clinical profiles and symptomatology [4], poorer
prognosis [5], relapses in both disorders [6, 7] and poorer
quality of life [8–10]. Therefore, treatment and recovery of
patients with dual diagnosis is a challenge for both drug
and mental health treatment providers. Several studies
have explored the best therapeutic approaches and strat-
egies to address these co-existing conditions and found
that integrated long-term interventions, disorder specific
cognitive-behavioral strategies and contingency manage-
ment have better results [11, 12].
Treatment approaches considering health-related qual-
ity of life (HRQoL) are likely to be more effective in pa-
tients with substance use disorder, as they address social
needs, adopt a chronic disease model of addiction and
track symptom severity and distress levels [13, 14].
Patient-perceived HRQoL has become an important out-
come in health care as an indicator of treatment effect-
iveness and recovery [15, 16]. While previous studies
have compared HRQoL between people with dual diag-
nosis and substance use disorder and/or severe mental
illness, no study has examined HRQoL among patients
with dual diagnosis and different mental health disor-
ders. Such data could be useful to inform possible tar-
geted treatments for dual diagnosis by providing a
subjective complementary perspective to clinicians,
reporting unique information about patients’ needs and
insights that could enhance the effectiveness of health
care [17, 18].
Patients with substance use disorder and co-existing
schizophrenia report poorer physical functioning, vitality
and, in general, lower HRQoL than patients with sub-
stance use disorder [19, 20]. In addition, they report
poorer social functioning and more emotional problems
[10, 20] than patients with SZ. Patients with substance
use disorder and co-existing bipolar disorder,present
poorer physical and psychological health and more im-
pairments in their social relationships than patients with
bipolar disorder only, substance use disorder only,and
healthy controls [21, 22]. Depressive symptoms [23], sui-
cide attempts [24], illicit drug use [25] and medical dis-
ease comorbidity [23, 25] were also associated with a
reduced HRQoL in patients with bipolar disorder. More-
over, HRQoL in patients with bipolar disorder is lower,
even though they do not experience (hypo) manic or de-
pressive episodes [26].
Regarding patients with substance use disorder and
comorbid major depressive disorder, alcohol use was re-
lated to poorer physical health, psychological function-
ing, social relationships, and environmental factors [27],
while general health perception and role-emotional were
negatively correlated with depressive symptomatology
[28, 29]. Although such findings contribute to an under-
standing of dually diagnosed patients, the possible differ-
ences among them depending on their severe mental
illness remain unknown.
As HRQoL measures in patients can greatly assist cli-
nicians to develop models that engage patients as part-
ners in their own care [17], we examined for the first
time, the possible differences in HRQoL in a sample of
patients with substance use disorder and different co-
morbid severe mental illness (substance use disorder
with co-existing: schizophrenia, bipolar disorder, and
major depressive disorder), to determine associated fac-
tors. Moreover, we compared HRQoL for patients with
substance use disorder according to their severe mental
illness with Spanish population norms to guide clinicians
about possible treatment needs related to comorbidity.
This study provides data that encourages the adoption
of an integrated recovery-oriented model that considers
wider outcomes than abstinence as the main goal of
treatment since poor quality of life is not only addiction-
specific [12, 30].
Methods
Study design, participants and procedure
Participants were recruited from public and private sub-
stance use disorder treatment centers from Barcelona,
Spain. Psychiatrists and psychologists informed potential
eligible patients about the study and arranged a time for
the researcher to discuss the study in detail before
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gaining their informed consent to participate. Those par-
ticipants providing informed consent were included in
the study if they were: (1) male; (2) aged between 18 to
55 years old; (3) had a current diagnosis of substance
use disorder in remission for at least three months but
were still receiving substance use disorder treatment; (4)
reported no substance use disorder relapses for at least
one month before participation in the study; (5) had a
current diagnosis of schizophrenia, bipolar disorder or
major depressive disorder; and (6) were able to complete
instruments in Spanish. Only male participants were in-
cluded as the majority of patients in treatment for sub-
stance use disorder are men [8], and the prevalence of
severe mental illness in substance use disorder also
tends to be higher in men than in women [2, 10]. The
exclusion criteria were: (1) meeting DSM-IV-TR criteria
for a current substance-induced psychiatric disorder or a
psychiatric disorder due to a medical condition and (2)
unstable or uncontrolled psychiatric symptomatology.
Severe mental illness was diagnosed in all patients in our
sample before participating in our study. This process
ensured that patients were in a clinical stable condition
to participate and that they did not present other
symptoms not related to their psychiatric diagnosis of
schizophrenia, bipolar disorder, or major depressive
disorder. The sample comprised 107 male patients
with a substance use disorder and comorbid severe
mental illness, with a mean age of 39.78 years
(SD = 8.11). Patients were not compensated for their
participation in the research. These patients were all
diagnosed with substance use disorder and co-existing:
schizophrenia (n = 37), bipolar disorder (n = 34), or
major depressive disorder (n = 36). A trained psycholo-
gist administered all clinical assessments, and patients
completed the SF-36 Health Survey alone or with the
help of the psychologist if required due to poor literacy
skills. Figure 1 describes the assessment and recruit-
ment of patients.
Assessment instruments
Structural clinical interview for DSM-IV-TR Axis I disorders
(SCID-I)
Current diagnoses of substance use disorder and severe
mental illness were obtained by treatment providers of
each respective participant and confirmed through ad-
ministration of the SCID-I [31]. SCID-I and a clinical
interview design for our study were used to assess socio-
demographic (e.g. age, marital status, social class,
schooling and economic status) and clinical variables
(e.g. psychiatric and substance use family history, age of
onset of the disorder and consumption, relapses, abstin-
ence periods, type of drugs used, suicide attempts, pres-
ence of organic pathology and medication).
The short form 36 health survey (SF-36)
The SF-36 [32] is a 36-item measure of HRQoL and
consists of eight primary components: Physical Func-
tioning, Role-Physical, Role-Emotional, Social Function-
ing, Mental Health, General Health, Bodily Pain, and
Vitality. Scores in the SF-36 range from 0 to 100, where
a higher score indicates a better health related quality of
life. The SF-36 includes an additional self-perceived item
measuring changes in general health over the last year
(Health Transition item). The scale provides two second-
ary composite standardized scales using T scores (with a
mean of 50 and standard deviation of 10): the Physical
Health Component Summary and the Mental Health
Component Summary. The SF-36 Spanish version was
used as it demonstrated good psychometric properties
and reference population values [33].
Drug abuse screening test (DAST-20)
The Spanish version of the DAST-20 [34] was used to
assess severity of substance use disorder as it showed ad-
equate psychometric properties [35]. The DAST-20 is
composed of 20 questions and provides a total severity
score from 0 to 20 (1–5 low, 6–10 intermediate, 11–15
substantial, 16–20 severe).
Positive and negative syndrome scale (PANSS)
Psychotic symptomatology was measured in the comor-
bid schizophrenia group using the Spanish version of the
PANSS [36], which has been described as a reliable in-
strument [37]. The PANSS is a 30-item scale measures
four areas related to different symptomatology: Positive
Syndrome, Negative Syndrome, Composite Scale, and
General Psychopathology. The Positive and Negative
Syndrome direct scores ranges from 7 to 49, while the
General Psychopathology ranges from 16 to 112. The
Composite Scale shows the predominance of positive or
negative symptoms and its direct score ranges from −42
to 42 (Positive minus Negative direct scores). All PANSS
direct scores were transformed to percentiles according
to Spanish normative data [37].
Young mania rating scale (YMRS)
The YMRS [38] was used to measure manic symptomatol-
ogy in the comorbid bipolar disorder group. The Spanish
Version of the YMRS is a useful, valid and reliable tool for
the assessment of manic symptoms [39]. This instrument
is an 11-item clinical scale designed to assess the severity
of manic symptoms in several areas (e.g. elevated mood,
increased motor activity/energy, sexual interest, sleep).
Each item includes four explicitly defined levels of sever-
ity. Severity ratings are based on the patient’s subjective
report of his clinical condition during the last 48 h and
the clinician’s observations during the interview. The total
score related to the severity of the affective state following
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these criteria: < 6 euthymic, 7–12 subclinical symptoms,
13–20 hippomanic and >20 manic episode.
Hamilton depression rating scale (HDRS)
The Spanish version of the 17-item version HDRS was
used to measure depressive symptomatology in the co-
morbid bipolar disorder and major depressive disorder
groups. This version showed good psychometric proper-
ties [40, 41]. The HDRS total score ranges from 0 to 53
and is interpreted as follows: 0–7 no depression, 8–13
low, 14–18 mild, 19–22 severe, and >23 very severe de-
pressive symptoms [41].
Statistical analysis
Descriptive statistics were used to describe the sociodemo-
graphic and clinical profile of the sample. Intergroup
differences were explored by performing univariate analyses
(ANOVA) for continuous data and Chi Square tests for cat-
egorical data. Multivariate Analyses of Covariance (MAN-
COVA) and post-hoc analyses were applied to explore
differences in HRQoL dimensions among the three groups,
with group as the fixed factor and age as a covariate as it
could be a confounding factor [42]. Bonferroni correction
was applied to address the problem of multiple compari-
sons and to protect against type I errors. Partial eta square
was obtained as a measure of MANCOVA/ANOVA effect
size (0.01 small; 0.06 medium; 0.14 large) as well as Cohen’s
d (0.2 small; 0.5 medium; 0.8 large) for post-hoc contrasts
[43]. Moreover, to obtain evidence about the degree of im-
pairment in the HRQoL dimensions, T scores (mean = 50;
SD = 10) were calculated for primary SF-36 dimensions of
each group according to Spanish population norms [33].
Fig. 1 Flowchart of participant recruitment and assessment protocol
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Bivariate correlational analysis between clinical vari-
ables and SF-36 dimensions were performed to explore
correlates of HRQoL in each group. Categorical variables
were dummy coded for further analyses. Only variables
that correlated with HRQoL in bivariate analyses and
showed a ß standardized coefficient ≥ 0.4, were retained
for the multiple stepwise regression analyses performed
to determine factors related to HRQoL dimensions
among the three groups. Data were analyzed using the
IBM SPSS Statistics version 22 [44].
Results
Study sample characteristics
Tables 1 and 2 summarize the sociodemographic and
clinical data for the three groups. Groups differed signifi-
cantly by age (p = 0.012), years of schooling (p = 0.039),
and economic situation (p = 0.005). Clinical variables,
such as medical disease comorbidity (p = 0.032), daily
amount of medications (p = 0.038) and the age of severe
mental illness onset (p < 0.001), were also significantly
different among the groups. Substance use disorder pa-
tients with comorbid schizophrenia were younger than
patients with comorbid major depressive disorder and
have fewer years of schooling than those with comorbid
bipolar disorder. A greater proportion of patients with co-
existing bipolar disorder were receiving a disability pen-
sion, these patients also had the lowest rate of medical
disease comorbidity. Patients with comorbid major de-
pressive disorder were the oldest and a higher proportion
was employed compared to patients in the other two
groups. The group with co-existing major depressive dis-
order also had the highest rate of medical disease comor-
bidity and the oldest age of severe mental illness onset.
All participants showed substantial severity of addic-
tion (DAST-20) with no differences observed among the
groups. Patients with comorbid schizophrenia showed
low percentile scores in each dimension of the PANSS.
For patients with comorbid major depressive disorder,
we observed a higher depressive symptomatology than
for patients with comorbid bipolar disorder (p = 0.002),
who were euthymic according to the YMRS score.
Health-related quality of life
Mean scores in all the primary SF-36 dimensions for the
three groups are shown in Table 3. Differences among the
groups were found in two primary SF-36 dimensions:
Physical Functioning (p = 0.002) and Vitality (p = 0.003);
while only the secondary Physical Composite Scale
showed differences among the three groups (p = 0.001).
Post-hoc analyses revealed poorer Physical Functioning
for patients with substance use disorder and co-existing
schizophrenia (p = 0.001; Cohen’s d = 0.687) and with co-
existing major depressive disorder (p = 0.044; Cohen’s
d = 0.797) compared to patients with comorbid bipolar
disorder, and lower Vitality for patients with comorbid
schizophrenia than for patients with comorbid bipolar dis-
order (p = 0.006; Cohen’s d = 0.727) and major depressive
disorder (p = 0.020; Cohen’s d = 0.695).
Moreover, the Physical Composite Summary Scale
showed lower scores for patients with co-existing schizo-
phrenia (p = 0.001; Cohen’s d = 0.863) and major depres-
sive disorder (p = 0.014; Cohen’s d = 0.703) than patients
with co-existing bipolar disorder. No significant differences
were observed among the groups in the other SF-36
dimensions.
Figure 2 compares means for the SF-36 dimensions for
the three substance use disorder groups with comorbid
severe mental illness and the Spanish population norms
[33]. Mean scores for the three groups were lower (−1
or −2 SD) than the Spanish normative data in all the pri-
mary SF-36 dimensions except for the group with co-
morbid bipolar disorder in Physical Functioning and
Role-Physical. The lowest scores were observed in pa-
tients with comorbid schizophrenia for Social Function-
ing, Role-Emotional and Vitality.
Factors contributing to health-related quality of life
Table 4 shows all linear regression models (only independ-
ent variables p < 0.05 were included in the model) for each
of the HRQoL dimensions measured by the SF-36. Clin-
ical variables, such as age of substance use disorder and
severe mental illness onset, average number of medica-
tions per day, mean abstinence period, duration of the
substance use disorder and severe mental illness, did not
correlate significantly with HRQoL dimensions in any of
the groups. The main results from the regression analyses
indicated several clinical variables related to SF-36 dimen-
sions by type of co-existing severe mental illness.
For the comorbid schizophrenia group, positive symp-
toms (PANSS) (p = 0.002) and medical disease comorbid-
ity (p = 0.030) were negatively related to Social
Functioning and explained 40.8% of the variance (F
(1,35) = 7.560; p = 0.004). Suicide attempts were negatively
linked to Role-Physical accounting for 14% of the variance
(F (1,35) = 6.556; p = 0.015) and Mental Health was nega-
tively related to medical disease comorbidity explaining
34.7% of the variance (F (1,35) = 6.851; p = 0.020).Vitality
was negatively linked to drug relapses which accounted
for 44.8%of its variance (F (1,35) = 8.112; p = 0.017), while
Bodily Pain was negatively related to PANSS composite
score scale accounting for 24.7% of the variance (F
(1,35) = 7.900; p = 0.011). The severity of the substance use
disorder and suicide attempts were not retained in the re-
gression models for the comorbid schizophrenia group.
For patients with co-existing bipolar disorder, suicide at-
tempts were negatively associated to Role-Physical which
explained 19.3% of the variance (F (1,32) = 8.665; p = 0.006)
and medical disease comorbidity was negatively linked to
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Table 1 Sociodemographic and clinical characteristics for substance use disorder patients with comorbid severe mental illness
Substance use disorder groups with comorbid severe mental illness
Schizophrenia
(n = 37)
Bipolar disorder
(n = 34)
Major depressive
disorder
(n = 36)
ANOVA and
Chi-Square
Post-hoc contrasts
Sociodemographic characteristics
Age (yr) 37.78 ± 8.03 38.56 ± 8.85 42.97 ± 6.54 F (2105) = 4.581* 0.775 (schizophrenia = bipolar
disorder)
5.188* (schizophrenia > major
depressive disorder)
0.413 (schizophrenia = major
depressive disorder)
Living situation χ2 (2) = 0.496
Living alone 25% 23.5% 30.6%
Married or co-habiting 75% 76.5%% 69.4%
Years of schooling 10.60 ± 2.40 12.42 ± 3.75 11.42 ± 2.44 F (2105) = 3.344* 1.824*(schizophrenia < bipolar
disorder)
0.817 (schizophrenia = major
depressive disorder)
1.008 (bipolar disorder = major
depressive disorder)
Economic situation χ2 (8) = 10.597**
Employed
Receiving unemployment
benefits
Disability pension
No income
8.1%
21.6%
56.8%
13.5%
8.8%
14.7%
67.6%
9%
27.8%
25.0%
33.3%
13.9%
Clinical characteristics
Medical disease comorbidity
Hypercholesterolemia
Breathing system pathology
Discal herniation
Epilepsy
HIV and/or Hepatitis (B/C)
Obesity
31.4%
8.6%
5.7%
2.8%
5.7%
8.6%
0%
27.3%
9.4%
12.5%
0%
0%
2.3%
0%
55.6%
22.4%
2.8%
5.6%
5.6%
15.7%
3.5%
χ2 (2) = 6.855*
Average number of medications
per day
2.50 ± 1.13 2.24 ± 1.10 1.83 ± 1.06 F (2105) = 3.365* 0.265 (schizophrenia = bipolar
disorder)
0.667* (schizophrenia > major
depressive disorder)
0.402 (bipolar disorder = major
depressive disorder)
Substance usea
Alcohol 72.97% 82.35% 81% χ2 (2) = 1.919
Cocaine 72.97% 70.27% 64.2% χ2 (2) = 1.060
Cannabis 81.08% 66.5% 52.7% χ2 (2) = 1.818
Amphetamines 14.4% 18.3% 16.8% χ2 (2) = 1.162
Opioids 5.8% 6% 8.4% χ2 (2) = 2.243
Poly drug use 51.6% 48.4% 44.5% χ2 (2) = 1.237
Number of suicide attempts 1.46 ± 1.33 1.42 ± 2.89 0.83 ± 0.97 F (2105) = 1.217
Mean abstinence period
(months)
6.03 ± 3.61 6.18 ± 3.49 5.44 ± 2.51 F (2, 105) = 0.505
Number of relapses in the
last year
1.94 ± 1.95 1.94 ± 2.87 1.63 ± 1.80 F (2105) = 0.222
Age of SMI onset (yr) 23.32 ± 5.80 26.29 ± 9.27 32.06 ± 8.75 F (2105) = 10.383*** 3.580 (schizophrenia = bipolar
disorder)
8.732*** (schizophrenia < major
depressive disorder)
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Role-Emotional explaining 47.6% of the variance (F
(1,32) = 12.791; p = 0.004). Finally, severity of addiction
(DAST-20) was negatively linked to Mental Health and
accounted for 42.7% of the variance (F (1,32) = 9.960;
p = 0.009). For patients with comorbid bipolar disorder
clinical variables including manic and depressive symp-
toms were not retained in the regression models.
For the comorbid major depressive disorder group,
medical disease comorbidity was negatively related to
Physical Functioning, accounting for 32.6% of the vari-
ance (F (1,34) = 17.964; p < 0.001), and to Role-Physical
explaining the 20.9% (F (1,34) = 10.274; p = 0.003). More-
over, depressive symptoms (HDRS) were negatively asso-
ciated with Mental Health accounting for 48.2% of the
variance (F (1,34) = 14.962; p = 0.002) and medical disease
comorbidity was negatively associated to General Health
and accounted for 22.2% of its variance (F (1,32) = 10.995;
p = 0.002). For patients with comorbid major depressive
disorder, suicide attempts and severity of the substance
use disorder were not retained in the regression analyses.
With regards to the SF-36 secondary dimensions,
clinically related factors were only observed within
the comorbid major depressive disorder group with
scores in the Physical Composite Scale negatively
linked to medical disease comorbidity (β = −0.684)
and explaining 44.1% of the variance (F (1,34) = 17.561;
p < 0.001).
Discussion
This study explores and compares for the first time the
differences in HRQoL among male patients with sub-
stance use disorder and different co-existing severe men-
tal illness. Patients with co-existing schizophrenia and
with co-existing major depressive disorder showed poorer
Physical Functioning and lower scores in the Physical
Composite Scale than patients with co-existing bipolar
disorder, while patients with comorbid schizophrenia
showed a lower Vitality than those with bipolar disorder
and major depressive disorder. Therefore, our results indi-
cate that the type of co-existing severe mental illness ap-
pears to influence some HRQoL dimensions. All patients
in our sample had poorer HRQoL (especially Social Func-
tioning, Role-Emotional and Mental Health) compared
with population norms. We only observed similar scores
to norms for patients with co-existing bipolar disorder
Table 1 Sociodemographic and clinical characteristics for substance use disorder patients with comorbid severe mental illness
(Continued)
Substance use disorder groups with comorbid severe mental illness
Schizophrenia
(n = 37)
Bipolar disorder
(n = 34)
Major depressive
disorder
(n = 36)
ANOVA and
Chi-Square
Post-hoc contrasts
5.152* (bipolar disorder < major
depressive disorder)
Age of SUD onset (yr) 17.15 ± 4.70 19.20 ± 8.60 18.57 ± 7.55 F (2105) = 0.633
Duration of the SMI (yr) 13.58 ± 8.09 12.51 ± 8.52 10.91 ± 9.04 F (2105) = 1.177
Duration of the SUD (yr) 19.76 ± 8.18 19.56 ± 9.82 24.57 ± 9.41 F (2105) = 3.254
aPatients were using more than one substance
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
Table 2 Comparison of clinical measures among men in treatment for substance use disorder patients by type of severe mental
illness
Clinical measures Substance use disorder groups with comorbid severe mental illness
Schizophrenia
(n = 37)
Bipolar disorder
(n = 34)
Major depressive
disorder (n = 36)
ANOVA
DAST-20 total score 12.06 ± 0.42 11.20 ± 1.22 14.13 ± 0.65 F (2105) = 3.331
PANSS Direct scores Percentile scores
Positive symptoms 10.63 ± 1.21 5
Negative symptoms 13.32 ± 1.65 15
Composite Score −2.69 ± 3.97 40
General Psychopathology 28.72 ± 2.80 10
HDRS total score 7.73 ± 0.60 12.18 ± 0.91 F (1,68) = 6.315*
YMRS total score 2.08 ± 0.57
DAST-20: Drug Abuse Screening Test; PANSS: Positive and Negative Syndrome Scale: HDRS: Hamilton Depression Rating Scale; YMRS: Young Mania Rating Scale
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
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Table 3 Comparison of SF-36 dimension scores among men in treatment for substance use disorder by type of severe mental
illness
Substance use disorder groups with comorbid severe mental illness
SF-36 dimensions Schizophrenia
(n = 37)
Bipolar
disorder
(n = 34)
Major depressive
disorder
(n = 36)
F Partial Eta
Square
Post-hoc contrasts
Physical Functioning 80.13 ± 3.27 94.26 ± 1.93 81.97 ± 3.11 6.836** 0.117 14.484*** (schizophrenia < bipolar disorder)
4.209 (schizophrenia = major depressive
disorder)
10.276* (bipolar disorder > major depressive
disorder)
Social Functioning 67.92 ± 5.06 70.65 ± 5.24 71.27 ± 3.68 0.179 0.003
Role-Physical 71.53 ± 5.91 87.55 ± 4.66 69.68 ± 5.78 2.877 0.053
Role-Emotional 62.60 ± 6.91 58.57 ± 3.82 42.61 ± 6.58 2.293 0.43
Mental Health 50.15 ± 3.25 51.01 ± 3.82 53.78 ± 2.93 0.251 0.005
Vitality 41.6 ± 2.80 55.68 ± 3.66 53.63 ± 2.92 6.044** 0.105 14.148** (schizophrenia < bipolar disorder)
12.597* (schizophrenia < major depressive
disorder)
1.552 (bipolar disorder = major depressive
disorder)
Bodily Pain 76.56 ± 4.59 76.68 ± 4.70 68.57 ± 4.33 0.860 0.16
General Health
Perception
57.69 ± 2.95 62.05 ± 4.01 56.69 ± 3.26 0.565 0.011
Health Changes 61.36 ± 3.94 69.85 ± 5.46 73.61 ± 4.45 1.694 0.032
Physical Composite
Scale
51.06 ± 1.41 60.40 ± 2.17 51.99 ± 1.87 7.464*** 0.127 9.458*** (schizophrenia < bipolar disorder)
1.766 (schizophrenia = major depressive
disorder)
7.692* (bipolar disorder > major depressive
disorder)
Mental Composite
Scale
37.58 ± 1.79 39.36 ± 3.42 38.61 ± 2.00 0.172 0.003
SF-36: Short Form Health Survey
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
Fig. 2 T scores (mean = 50; SD = 10) for the three groups of patients with substance use disorder and severe mental illness in the 36-Item Short
Form Health Survey (SF-36) according to Spanish population norms
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in Physical Functioning and Role-Physical. Our results
extend previous findings [18–22, 26–29] as some of
the HRQoL dimensions were impaired for the three
groups of patients in our sample when compared to
population norms.
Firstly, we observed major difficulties for patients with
comorbid schizophrenia and major depressive disorder
as they showed poorer Physical Functioning than pa-
tients with bipolar disorder and population norms.
These results extend previous findings [18–20, 27] about
schizophrenia and major depressive disorder patients be-
ing more likely to experience difficulties in developing
vigorous activities, lifting and carrying groceries, using
stairs, and walking. Secondly, scores in Vitality showed
that comorbid schizophrenia patients were more fre-
quently tired and worn out than those patients with bi-
polar disorder, major depressive disorder, and population
norms. Contrary to previous findings, no relation was
found between tiredness and daily amount of medica-
tions [20] for patients with comorbid schizophrenia.
This fact could be explained by the stable clinical situ-
ation in our sample for both substance use disorder and
schizophrenia diagnoses as they were receiving mainten-
ance doses of antipsychotics.
Lastly, only one of the secondary composite scales
showed differences among groups. Patients with comor-
bid schizophrenia and major depressive disorder showed
lower scores in the Physical Composite Summary Scale
than patients with comorbid bipolar disorder; this fact
could be explained by their limitations in physical activ-
ities (poorer Physical Functioning), and for patients with
comorbid major depressive disorder, by the presence of
medical disease comorbidity. No clinical variables were
related to the Physical Composite Summary Scale for pa-
tients with co-existing schizophrenia or bipolar disorder.
However, and in line with previous studies [28, 29],
medical disease comorbidity was negatively related to
the Physical Composite Summary Scale for patients with
co-existing major depressive disorder. Thus, medical dis-
ease comorbidity in patients with major depressive dis-
order could be a confounding factor, potentially related
to the older age of these patients, which future studies
should take into account and explore in detail. Never-
theless, medical comorbidities in patients with substance
Table 4 Clinical variables and the SF-36 for substance use disorder patients with severe mental illness
Substance use disorder groups with comorbid severe mental illness Major depressive disorder (n = 36)
Schizophrenia (n = 37) Bipolar disorder (n = 34)
SF-36
Dimension
Adjusted R2 IV ß standardized Adjusted R2 IV ß standardized Adjusted R2 IV ß standardized
Physical
Functioning
0.326 Medical
disease
comorbidity
−0.588***
Social
Functioning
0.408 Positive
symptoms
(PANSS)
−0.650**
Medical
disease
comorbidity
−0.432*
Role-Physical 0.140 Suicide
attempts
−0.407* 0.193 Suicide attempts −0.467** 0.209 Medical
disease
comorbidity
−0.482**
Role-
Emotional
0.476 Medical disease
comorbidity
−0.718**
Mental
Health
0.347 Medical
disease
comorbidity
−0.638* 0.427 Severity of
substance
use disorder
(DAST-20)
−0.689** 0.482 Depressive
symptoms
(HDRS)
−0.719**
Vitality 0.448 Drug
relapses
−0.669*
Bodily Pain 0.247 PANSS
composite
score
−0.532* 0.177 Depressive
symptoms
(HDRS)
−0.469*
General
Health
0.222 Medical
disease
comorbidity
−0.494**
SF-36: Short Form Health Survey
In all cases Tolerance values were higher than 0.954 and Variance Inflation Factor were higher than 1
*p < 0.05, **p < 0.01; ***p < 0.001
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use disorder and major depressive disorder could be es-
pecially taken into account during their substance use
disorder treatment as previous research has shown that
targeting somatic comorbidities may play an important
role in improving HRQoL [45].
Likewise, we observed that different clinically related
factors were contributing to different HRQoL depending
on the type of severe mental illness. For patients with
co-existing schizophrenia positive symptoms and med-
ical disease comorbidity were related to poorer Social
Functioning, suicide attempts were associated to a worse
Role-Physical, the presence of medical disease comorbid-
ity was linked to worse Mental Health, drug relapses
were negatively to a lower Vitality and the predominance
of negative symptoms was associated with Bodily Pain.
For patients with co-existing bipolar disorder, a worse
Role-Physical was associated with suicide attempts, med-
ical disease comorbidity was linked to worse Role-
Emotional and a higher severity of the substance use dis-
order was linked to a worse Mental Health. These re-
sults for patients with comorbid bipolar disorder extend
previous data explaining the association among suicide
attempts [24], medical disease comorbidity [23] and
HRQoL impairments for patients with bipolar disorder.
Regarding patients in the comorbid major depressive dis-
order group, poorer Physical Functioning, and poorer
Role-Physical were associated with the presence of medical
disease comorbidity. In line with previous data [28, 29]
higher depressive symptoms were associated with a worse
Mental Health while medical disease comorbidity was
linked to a worse General Health.
The differences we observed among groups have clin-
ical implications and highlight the need to adjust treat-
ment approaches to address such difficulties especially
among substance use disorder male patients with co-
morbid schizophrenia and with comorbid major depres-
sive disorder. For instance, substance use disorder
treatments could include self-directed exercise, as it is
an effective way to improve Physical Functioning [46],
and positive compensation strategies to enhance patients’
performance capacity [47]; as these interventions improve
physical and general wellbeing [48]. To potentially im-
prove Vitality, especially in patients with substance use
disorder and co-existing schizophrenia fatigue and low
energy levels could be addressed with interventions that
use motivational strategies to engage patients in exercise
emphasizing that working-out may ameliorate these
symptoms too. Similarly, treatment could include stra-
tegies to manage other Vitality related factors such as
sleep, since previous studies found that better sleep quality
improves HRQoL and increases energy levels [49].
Furthermore, consistent with previous observations
about different substance use disorder and/or severe men-
tal illnesses [9, 19–22], our findings showed impaired
HRQoL dimensions (especially Social Functioning, Role-
Emotional, and Mental Health) in the three groups
compared to population norms; except for Physical
Functioning and Role-Physical in comorbid bipolar dis-
order patients. A normal Physical Functioning and
Role-Physical for patients with bipolar disorder accord-
ing to norms could be potentially explained by patients
in this group being euthymic and having the lowest
rates for medical disease comorbidity. In this sense, pa-
tients with substance use disorder and co-existing bipo-
lar disorder had better clinical characteristics than
those with schizophrenia and with major depressive
disorder. Dually diagnosed male patients in our sample
experienced frequent limitations with normal social ac-
tivities due to emotional problems (poorer Social Func-
tioning) and this was more notable for those patients
with comorbid schizophrenia and related to their posi-
tive symptomatology. A potential explanation of these
results could be the burden of severe mental illness and
the impact of drug dependence in the relationship be-
tween the individual and its social network; patients in
our sample were in a clinically stable but not com-
pletely asymptomatic during our assessment. Patients
from all groups, and especially those with co-existing
major depressive disorder, had difficulties with work or
other daily activities as a result of emotional problems
(poorer Role-Emotional); these difficulties were posi-
tively associated with suicide attempts for patients with
comorbid schizophrenia. All patients frequently reported
feelings of nervousness and depression (worse Mental
Health) and this was especially associated with medical
disease comorbidity for patients with schizophrenia, the
severity of addiction for bipolar disorder, and depressive
symptomatology for major depressive disorder.
Our results support the importance of an integrated
recovery model [12, 15, 30] that does not only consider
abstinence as the main therapeutic goal for patients
with substance use disorder and psychiatric comorbid-
ity. For instance, treatments for substance use disorder
male patients with co-existing schizophrenia should in-
clude strategies to increase social activities (e.g. group
activities for a better Social Functioning); while interven-
tions targeted at male patients with co-exiting major de-
pressive disorder should include techniques to cope with
depressive symptoms (e.g. behavioral activation to improve
Role-Emotional). Besides, for male patients with substance
use disorder and a co-existing schizophrenia, bipolar dis-
order or major depressive disorder, treatments should con-
sider strategies to manage emotional problems (e.g. coping
strategies focused on emotion) and reduce anxiety (e.g. re-
laxation techniques) as they had poorer Mental Health
than population norms. Such strategies could improve pa-
tients´ HRQoL and therefore, enhance their functioning
and treatment adherence [15, 17].
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Limitations
The present study has some potential limitations. The
cross-sectional design only allowed us to explore the
weight of each psychiatric condition, as we could not in-
vestigate causal relationships between substance use dis-
order, comorbid severe mental illness and HRQoL. The
sample size was small and only included substance use
disorder male patients with schizophrenia, bipolar dis-
order, and major depressive disorder who were receiving
treatment for addiction. Therefore, our results can only
be extended to male patients in treatment for substance
use. In addition, data were based on partially retrospect-
ive self-reported information that may have been subject
to recall bias. Further studies should include females and
compare results by gender. Adequately powered samples
using a longitudinal design could assess the impact of
treatment on HRQoL.
Despite these limitations, our study supports the im-
portance of assessing and managing HRQoL in male pa-
tients with substance use disorder and severe mental
illness as they showed poorer HRQoL. Therefore, sub-
stance use disorder treatments should be matched to dif-
ferent types of severe mental illness, as poorer HRQoL
found in some dimensions differed according to the co-
existing severe mental illness. Hence, future studies
examining HRQoL in patients with substance use dis-
order should consider comorbidity as a mediating factor
as it is linked to both substance use disorder and psychi-
atric variables [14, 25] and is one of the recommended
outcome measures that could help to improve clinical
care and design tailored treatment approaches [15, 16].
Conclusions
In summary, male patients with substance use disorder
showed differences in HRQoL depending on the type of
co-existing severe mental illness. Patients with substance
use disorder and comorbid schizophrenia and with co-
morbid major depressive disorder showed poorer Physical
Functioning than those with comorbid bipolar disorder,
while those with comorbid schizophrenia showed the low-
est Vitality. Different clinical variables (e.g. medical disease
comorbidity, severity of addiction, drug relapses and psy-
chiatric symptoms) were related to different HRQoL di-
mensions depending on the co-existing severe mental
illness diagnosis. In addition, compared to Spanish popu-
lation norms, Social Functioning, Role-Emotional, and
Mental Health dimensions were significantly lower in the
three groups. We only observed scores similar to norms
for patients with substance use disorder and comorbid bi-
polar disorder in Physical-Functioning and Role-Physical.
Therefore, among male patients with substance use dis-
order, the type of severe mental illness could influence
some HRQoL dimensions as well as their clinically related
variables.
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